179 related articles for article (PubMed ID: 8526185)
1. Optimal number of chemotherapy courses in advanced nonseminomatous testicular carcinoma.
Kennedy BJ; Torkelson J; Fraley EE
Am J Clin Oncol; 1995 Dec; 18(6):463-8. PubMed ID: 8526185
[TBL] [Abstract][Full Text] [Related]
2. Adequacy of chemotherapy prior to cytoreductive surgery in testicular carcinoma.
Kennedy BJ; Torkelson JL; Fraley EE
Am J Clin Oncol; 1996 Dec; 19(6):541-5. PubMed ID: 8931667
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy for stage II nonseminomatous germ cell cancer of the testis.
Kennedy BJ; Torkelson JL; Fraley EE
Cancer; 1994 Mar; 73(5):1485-9. PubMed ID: 7509255
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for testicular cancer.
Xiao H; Sheinfeld J; Motzer RJ
Surg Oncol Clin N Am; 1997 Oct; 6(4):863-78. PubMed ID: 9309098
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
Culine S; Theodore C; Farhat F; Bekradda M; Terrier-Lacombe MJ; Droz JP
J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
[TBL] [Abstract][Full Text] [Related]
6. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial.
Pont J; Albrecht W; Postner G; Sellner F; Angel K; Höltl W
J Clin Oncol; 1996 Feb; 14(2):441-8. PubMed ID: 8636755
[TBL] [Abstract][Full Text] [Related]
9. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).
Dearnaley DP; Fossa SD; Kaye SB; Cullen MH; Harland SJ; Sokal MP; Graham JD; Roberts JT; Mead GM; Williams MV; Cook PA; Stenning SP;
Br J Cancer; 2005 Jun; 92(12):2107-13. PubMed ID: 15928672
[TBL] [Abstract][Full Text] [Related]
11. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
[TBL] [Abstract][Full Text] [Related]
12. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
Srougi M; Simon SD; de Góes GM
J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
[TBL] [Abstract][Full Text] [Related]
13. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
14. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG).
Germà-Lluch JR; Garcia del Muro X; Tabernero JM; Sánchez M; Aparicio J; Alba E; Barnadas A
Ann Oncol; 1999 Mar; 10(3):289-93. PubMed ID: 10355572
[TBL] [Abstract][Full Text] [Related]
15. Treatment in germ cell tumours: state of the art.
Tjan-Heijnen VC; Oosterhof GO; de Wit R; De Mulder PH
Eur J Surg Oncol; 1997 Apr; 23(2):110-7. PubMed ID: 9158183
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
17. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
Amato RJ; Ro JY; Ayala AG; Swanson DA
Urology; 2004 Jan; 63(1):144-8; discussion 148-9. PubMed ID: 14751368
[TBL] [Abstract][Full Text] [Related]
18. Treatment of testicular cancer: a new and improved model.
Einhorn LH
J Clin Oncol; 1990 Nov; 8(11):1777-81. PubMed ID: 1700077
[TBL] [Abstract][Full Text] [Related]
19. Primary chemotherapy for stage 2 testis cancer.
Abratt RP; McAdam GL; Pontin AR; Barnes RD; Ball HS
S Afr J Surg; 1997 Nov; 35(4):203-5; discussion 205-6. PubMed ID: 9540399
[TBL] [Abstract][Full Text] [Related]
20. [Lung residuals following chemotherapy in patients with stage III nonseminomatous testicular cancer. Report of 4 cases].
Ueda T; Yamauchi T; Kawai T; Ohno Y; Kawakami S; Yonese J; Tachibana Y
Nihon Hinyokika Gakkai Zasshi; 1994 Feb; 85(2):350-3. PubMed ID: 7509890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]